Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 1—January 2010
Research

Severe Pneumonia Associated with Pandemic (H1N1) 2009 Outbreak, San Luis Potosí, Mexico

Alejandro Gómez-GómezComments to Author , Martin Magaña-Aquino, Christian A. García-Sepúlveda, Uciel R. Ochoa-Pérez, Reynaldo Falcón-Escobedo, Andreu Comas-García, Saray Aranda-Romo, Hugo I. Contreras-Treviño, Paulina V. Jiménez-Rico, Mario A. Banda-Barbosa, Félix Dominguez-Paulin, J. Mario Bernal-Blanco, Luis F. Pérez-González, and Daniel E. Noyola
Author affiliations: Hospital Central “Dr. Ignacio Morones Prieto,” San Luis Potosí, Mexico (A. Gómez-Gómez, M. Magaña-Aquino, R. Falcón-Escobedo, J.M. Bernal-Blanco, L.F. Pérez-González); Universidad Autónoma de San Luis Potosí, San Luis Potosí (A. Gómez-Gómez, M. Magaña-Aquino, C.A. García-Sepúlveda, U.R. Ochoa-Pérez, R. Falcón-Escobedo, A. Comas-García, S. Aranda-Romo, H.I. Contreras-Treviño, P.V. Jiménez-Rico, M.A. Banda-Barbosa, F. Dominguez-Paulin, J.M. Bernal-Blanco, L.F. Pérez-González, D.E. Noyola); Servicios de Salud del Estado de San Luis Potosí, San Luis Potosí (U.R. Ochoa-Pérez)

Main Article

Table 3

Demographic, clinical, and laboratory features on admission of patients with pandemic (H1N1) 2009 and nonconfirmed influenza pneumonia cases during the pandemic (H1N1) 2009 outbreak, San Luis Potosí, Mexico*

Characteristic Pandemic (H1N1) 2009
(n = 11) Nonconfirmed influenza
(n = 32) p value
Demographic features
Male sex 5 (45.5) 20 (62.5) 0.48
Age, y, mean (SD) 34 (10.97) 39.47 (14) 0.25
Resident of San Luis Potosí municipality
5 (45.5)
20 (62.5)
0.73
Clinical features
Presence of underlying conditions
Obesity (BMI >30)† 4 (40) 16 (57.1) 0.47
Diabetes 2 (18.2) 4 (12.5) 0.64
Other conditions‡ 3 (27.3) 4 (12.5) 0.35
Days from symptom onset to admission, mean (SD) 5.36 (2.5) 6.72 (3.13) 0.2
Duration of symptoms at the onset of dyspnea, d, mean (SD) 2.73 (1.19) 3.91 (1.92) 0.06
Pneumonia severity index (PORT score)
2.82 (1.47)
2.81 (1.15)
0.99
Symptoms
Fever 11 (100) 32 (100.0) NA
Headache 10 (90.9) 31 (96.9) 0.45
Cough 11 (100) 31 (96.9) 1
Myalgias 9 (81.8) 32 (100.0) 0.06
Arthralgias 10 (90.9) 30 (93.8) 1
Dyspnea 11 (100) 25 (78.1) 0.16
Rhinorrea 8 (72.7) 25 (78.1) 0.69
Malaise 6 (54.5) 11 (34.4) 0.29
Blood-streaked sputum 3 (27.3) 13 (40.6) 0.49
Diarrhea 1 (9.1) 7 (21.9) 0.66
Pleuritic chest pain 1 (9.1) 5 (15.6) 1
Vomiting
2 (18.2)
2 (6.3)
0.27
Physical examination findings on admission
BMI, mean (SD) 29.17 (6.48) 31.22 (5.4) 0.34
Respiratory rate, bpm, mean (SD) 28.44 (4.91) 28.31 (7.24) 0.92
Crackles 0.03
Unilateral 4 (36.4) 2 (6.3)
Bilateral 7 (63.6) 30 (93.8)
Wheezing
5 (45.5)
18 (56.3)
0.73
Laboratory features
Total leukocyte count on admission (x 109/L), median (SD) 8.81 (6.1) 6.81 (4.13) 0.23
Platelet count (x 109/L), mean (SD)§ 173.6 (61.48) 227 (216.24) 0.45
C-reactive protein, mg/dL, mean (SD) 14.51 (8.45) 18.74 (16.22) 0.41
Creatinine, mg/dL, median (SD) 1.24 (0.87) 1.11 (0.75) 0.13
Creatine phosphokinase, U/L, mean (SD) 376.78 (439.22) 462.2 (507.27) 0.65
Lactate dehydrogenase, U/L, median (SD)§ 952 (674.72) 1089.31 (602.32) 0.54
AST, mg/dL, median (range)¶ 43 (19–76) 69 (18–249) 0.07
ALT, mg/dL, median (range)# 29 (13–55) 43 (13–177) 0.05

*Values are no. (%) unless otherwise indicated. BMI, body mass index; bpm, breaths per minute; PORT, Pneumonia Patient Outcomes Research Team (www.ahrq.gov/clinic/pneuclin.htm); NA, not available; AST, aspartate aminotransferase; ALT; alanine transaminase.
†Data available for 38 patients.
‡Includes chronic renal failure, systemic lupus erythematosus, pregnancy, cardiac disorder, seizure disorder.
§Data available for 42 patients.
¶Data available for 41 patients.
#Data available for 40 patients.

Main Article

Page created: March 31, 2011
Page updated: March 31, 2011
Page reviewed: March 31, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external